

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Gp - 1644
Docket No.

A013 US

RECEIVED

In Re Application Of:

Browning, et al.

#3

SK 6/27/00

JUN 20 2000

Serial-No.

09/299,139

Filing Date

April 23, 1999

Examiner

not yet assigned

TECH CENTER 6A p6072900

not yet assigned

Title:

SOLUBLE LYMPHOTOXIN BETA RECEPTOR AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND
AGENTS FOR TREATMENT



Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

a certification as specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
A013 US

In Re Application Of:

Browning, et al.

RECEIVED

JUN 20 2000

Serial No.
09/299,139

Filing Date
April 23, 1999

Examiner
not yet assigned

TECH CENTER

Group Art Unit
1600/2900
not yet assigned

Title:

SOLUBLE LYMPHOTOXIN BETA RECEPTOR AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND
AGENTS FOR TREATMENT



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2327 as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Certificate of Transmission by Facsimile*


I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.

) on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate


*This certificate may only be used if paying by deposit account.



Signature

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on June 5, 2000 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Signature of Person Mailing Correspondence

Laura McGuire

Typed or Printed Name of Person Mailing Correspondence

Dated:

June 5, 2000

CC:

O P E JC95
JUN 19 2000
PATENT & TRADEMARK OFFICE

Docket No.: A013 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Examiner:

Browning, et al.

Group Art Unit:

Serial No.: 09/299,139

Filing Date: April 23, 1999


For: SOLUBLE LYMPHOTOXIN BETA RECEPTOR AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES AS THERAPEUTIC AGENTS FOR TREATMENT

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on:

June 5, 2000

Date



Laura M. McGuire

SUPPLEMENTAL COMMUNICATION

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The attached Information Statement Disclosure submitted herewith is being filed before the mailing date of a first Office Action on the merits and therefore no fee is due. In an abundance of caution, however, the Assistant Commissioner is hereby authorized to charge Deposit Account No. 02-2327 for any unforeseen fee that may be due.


In addition to the attached Information Statement Disclosure submitted herewith, Applicants are including a complementary copy of the International Search Report issued

for PCT application number PCT/US97/19436, on which the instant U.S. application is based.

If the Examiner believes that consideration of the application, or of any matter related to this submission, would be facilitated by a telephone conference with Applicants' attorney, the Examiner is urged to contact the undersigned at the telephone number set forth below.

Respectfully submitted,

Date: June 5, 2000



Niki D. Cox, Esq.
Reg. No. 42,446
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-2079 (Direct)
(617) 679-2838 (Facsimile)